Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITIC2 Trial: Topical imiquimod versus conization for cervical intraepithelial neoplasia
2012-004518-32Phase 3Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jan 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Successful treatment at 6 months. Started Jan 2013; status: terminated.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2012-004518-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004518-32.